ImmunoGen
ImmunoGen specialises in ADCs with maytansinoid and IGN payloads and has an approved product in ovarian cancer. Its focus remains largely single-antigen. Valink differentiates by developing dual-target V-Gate molecules intended to expand the addressable patient population beyond what ImmunoGen's current portfolio targets.
Free